BIO Worried CMS’ Alzheimer’s Coverage Is ‘Trial Balloon’ For Lower Accelerated Approval Reimbursement

 
• By Sarah Karlin-Smith
colorful balloons
BIO is concerned about future drug reimbursement challenges due to CMS’ view of accelerated approval. • Source: Shutterstock

More from Pricing Debate

More from Market Access